Donald C. Goff, MD
Dr. Goff is a translational clinical researcher who studies and treats schizophrenia.
Dr. Goff was the Director of the Schizophrenia Clinical and Research Program at the Massachusetts General Hospital (MGH) and Professor of Psychiatry at Harvard Medical School prior to moving to New York in 2012 to become the Marvin Stern Professor and Vice Chair for Research in Psychiatry at New York University Langone Medical Center and Director of the Nathan Kline Institute for Psychiatric Research. Dr. Goff earned his medical degree at UCLA and completed his internship in Internal Medicine at Cedars-Sinai Medical Center in Los Angeles and his residency in Psychiatry at MGH in Boston. His research fellowship in Psychopharmacology was completed at Tufts-New England Medical Center in Boston. Following training, he established the Schizophrenia Clinical and Research Program at the MGH of which he was Director for 25 years.
Dr. Goff has published over 200 articles concerning schizophrenia and related topics. At the MGH he developed a translational clinical research program integrating pharmacology, cognitive behavioral therapy, neuroimaging, and genetics to enhance our understanding of the pathophysiology of schizophrenia and to develop new treatments. This group has done pioneering work in the areas of functional imaging, metabolic effects of second generation antipsychotics, nicotine, glutamatergic agents and folate based on models from molecular neuroscience and following a personalized medicine approach. Dr. Goff is currently working in the areas of early intervention and the treatment of refractory symptoms employing strategies to enhance neuroprotection and neuroplasticity.
Dr. Goff is the recipient of the Kempf Award for Mentorship in Biological Psychiatry from the American Psychiatric Association; the Wayne Fenton, MD, Award for Exceptional Clinical Care; the Stanley Dean Award for Research in Schizophrenia from the American College of Psychiatrists and the Research Award from the American Psychiatric Association. He is also a member of the American College of Neuropsychopharmacology and Associate Editor for Psychiatry at JAMA.